Energy drinks: A contemporary issues paper
J Diabetes Investig 1(12):823 Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G et al (2019) Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
After several inspections, the cease and desist notice was lifted in December 2022
In addition to weight-loss benefits, Wegovy is indicated to reduce the risk of major cardiovascular events in obese or overweight adults with established cardiovascular disease
Additionally, Mohiuddin et al (165) indicated that GLP-1RAs exerted neuroprotective effects through direct action on root ganglion neurons
Mechanism, dosing, evidence, and what the research does not yet support